跳转至内容
Merck
CN

SML3203

Tebipenem

≥98% (HPLC), β-lactam antibiotic, powder

别名:

(1R,5S,6S)-2-[1-(1,3-Thiazolin-2-yl)azetidin-3-yl]thio-6-[(R)-1-hydroxyeth yl]-1-methyl-carbapen-2-em-3-carboxylic acid, (4R,5S,6S)-3-[[1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, L-084 active drug, LJC 11,036, LJC 11036, ME1211 active drug, SPR 859, SPR 994 active drug, SPR-859, SPR-994 active drug, SPR859, SPR994 active drug, TBM, TBM-PI active drug, Tebi-pivoxil active drug, [4R-[4α,5β,6β(R*)]]-3-[[1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C16H21N3O4S2
化学文摘社编号:
161715-21-5
分子量:
383.49
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
MFCD00936545
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Tebipenem, ≥98% (HPLC)

SMILES string

S1CCN=C1N2CC(C2)SC3=C(N4[C@H]([C@H]3C)[C@H](C4=O)[C@H](O)C)C(=O)O

InChI

1S/C16H21N3O4S2/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)25-9-5-18(6-9)16-17-3-4-24-16/h7-11,20H,3-6H2,1-2H3,(H,22,23)/t7-,8-,10-,11-/m1/s1

InChI key

GXXLUDOKHXEFBQ-YJFSRANCSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Quality Level

100

相关类别

Biochem/physiol Actions

Carbapenem class broad-spectrum β-lactam antibiotic, active metabolite of Tebipenem pivoxil (L-084I; SPR994; Tebi-pivoxil; TBM-P).
Tebipenem (LJC 11,036; SPR859; TBM) is a carbapenem class broad-spectrum β-lactam antibiotic against both gram-positive and gram-negative bacteria, including penicillin-resistant S. pneumoniae (PRSP) and many β-lactamase-producing strains (respective MIC ≤6-200 and ≤25-390 ng/mL), while being less effective against methicillin-resistant S. aureus (MRSA), S. marcescens, and P. aeruginosa (respective MIC ranges 0.2 to12.5, 0.05 to100, 3.13 to >100 μg/mL). TBM is 2- to 64-fold more potent than imipenem, cefdinir, and faropenem against clinical isolates from respiratory and urinary-tract infections.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000187272
0000180386
0000187272
0000187271
0000180386

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Aileen Rubio et al.
ACS infectious diseases, 4(10), 1436-1438 (2018-08-18)
Carbapenems are potent antibacterials with broad-spectrum activity. However, poor oral absorption generally confines this important drug class to in-hospital use by intravenous (IV) administration. The continued rise in drug resistant pathogens creates a need for alternative oral therapies with broad-spectrum
M Hikida et al.
Antimicrobial agents and chemotherapy, 43(8), 2010-2016 (1999-08-03)
LJC 11,036 is the active metabolite of L-084, a novel oral carbapenem that exhibits potent broad-spectrum activity. Antibacterial activities of LJC 11,036 against clinical isolates from respiratory infections, such as Streptococcus pneumoniae (n = 52), Streptococcus pyogenes (n = 19)
Qi Yao et al.
Molecules (Basel, Switzerland), 21(1), 62-62 (2016-01-12)
To systemically investigate the in vitro and in vivo antibacterial properties of tebipenem pivoxil tablet. In addition, acute toxicity of this preparation was also studied. In vitro, minimum inhibitory concentration (MIC) or minimal inhibitory concentration (MBC) were determined by using
Visanu Thamlikitkul et al.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 97(12), 1259-1268 (2015-03-15)
To determine in vitro and in vivo activity of tebipenem against ESBL-producing E. coli. Minimum inhibitory concentration (MIC) of tebipenem against 100 clinical isolates of ESBL-producing E. coli was performed by broth micro-dilution technique. Blood and urine samples from 10
Mario A Bianchet et al.
BMC biochemistry, 18(1), 8-8 (2017-05-27)
The carbapenem subclass of β-lactams is among the most potent antibiotics available today. Emerging evidence shows that, unlike other subclasses of β-lactams, carbapenems bind to and inhibit non-classical transpeptidases (L,D-transpeptidases) that generate 3 → 3 linkages in bacterial peptidoglycan. The
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持